

High interest for long-acting injectable PrEP among pregnant women taking daily oral PrEP in Kisumu and Siaya, Kenya



Tessa Concepcion

University of Washington

June 13, 2023

Funding acknowledgements




R01NR019220



F31HD112236




Background



mWACH-PrEP

- Ongoing RCT at 5 antenatal clinics in Kisumu and Siaya, Kenya (NCT04472884)
- Eligibility
 - HIV-negative
 - ≥ 18 years
 - 24-32 weeks gestation
 - High risk of HIV (HIV risk score ≥ 6 ,
~ 8.9 HIV infections per 100 person-years)
 - Newly initiating PrEP
- Followed through 9 months postpartum




Methods

Data on long-acting PrEP preferences collected starting November 2022

At each study visit

- Behavioral characteristics
- Social factors
- PrEP use
- Long-acting PrEP interest and implementation factors

Multinomial generalized estimating equation



Baseline characteristics



231

women contributed

495

visits in pregnancy



24 years

median age at
enrollment



87.0%

had a partner with
unknown HIV status



36.4%

primigravida



26 weeks

median gestational
age at enrollment




3.9%

had a partner living
with HIV



LA-PrEP interest among pregnant women



Total N	169	163	111	52	
Gestational age (weeks)	30.9 (2.8)	34.4 (2.5)	37.1 (1.9)	39.9 (1.9)	Mean (SD)
Time on PrEP (days)*	28.5 (5.8)	56.7 (7.4)	82.6 (9.9)	104.5 (13.9)	Mean (SD)
Discontinuing PrEP	14 (8.3)	26 (16)	19 (17.1)	10 (19.2)	N (%)




Interest in LA-injectable PrEP


- Very interested
- Interested
- Slightly interested
- Not all all interested

*Excluding participants who discontinued PrEP


LA-PrEP interest among pregnant women




LA-PrEP interest among pregnant women



LA-PrEP interest among pregnant women



PrEP use throughout pregnancy




Gestational age (weeks)	30.9 (2.8)	34.4 (2.5)	37.1 (1.9)	39.9 (1.9)	Mean (SD)
Time on PrEP (days)*	28.5 (5.8)	56.7 (7.4)	82.6 (9.9)	104.5 (13.9)	Mean (SD)
Discontinuing PrEP	14 (8.3)	26 (16)	19 (17.1)	10 (19.2)	N (%)
Missed any PrEP	84 (49.7)	57 (35.0)	44 (39.6)	30 (38.5)	N (%)



Factors associated with LA-PrEP interest

Level of interest



Predictors of interest

Behavioral characteristics


Social characteristics

PrEP use

Measured at up to 4 visits per participant during pregnancy



Factors associated with increased interest in LA-PrEP



Implications and next steps



High interest in long-acting injectable PrEP among pregnant women



Alternative PrEP methods may be appropriate for pregnant women with suboptimal adherence to daily oral PrEP



- Preferences for PrEP formulations
- Identify early process indicators for implementing long-acting PrEP into MCH systems



Thank you

Study team

John Kinuthia	Nancy Ngumbau
Felix Abuna	Jerusha Nyabiage
Eunita Akim	Ben Ochieng
Julia Dettinger	Salphine Watoyi
Laurén Gómez	Jillian Pintye
Emma Mukenyi	

Contributors

Study nurses
Participants

